Efficacy and safety of nivolumab in Japanese patients with advanced or recurrent squamous non-small cell lung cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and safety of nivolumab in Japanese patients with advanced or recurrent squamous non-small cell lung cancer

Published:2017-04-26 Issue:5 Volume:108 Page:1000-1006
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Hida Toyoaki¹,Nishio Makoto²,Nogami Naoyuki³,Ohe Yuichiro⁴,Nokihara Hiroshi⁴,Sakai Hiroshi⁵,Satouchi Miyako⁶,Nakagawa Kazuhiko⁷,Takenoyama Mitsuhiro⁸,Isobe Hiroshi⁹,Fujita Shiro¹⁰,Tanaka Hiroshi¹¹,Minato Koichi¹²,Takahashi Toshiaki¹³,Maemondo Makoto¹⁴,Takeda Koji¹⁵,Saka Hideo¹⁶,Goto Koichi¹⁷,Atagi Shinji¹⁸,Hirashima Tomonori¹⁹,Sumiyoshi Naoki²⁰,Tamura Tomohide²¹

Affiliation:

1. Aichi Cancer Center Hospital; Aichi Japan

2. The Cancer Institute Hospital; Japanese Foundation for Cancer Research; Tokyo Japan

3. National Hospital Organization Shikoku Cancer Center; Ehime Japan

4. National Cancer Center Hospital; Tokyo Japan

5. Saitama Cancer Center; Saitama Japan

6. Hyogo Cancer Center; Hyogo Japan

7. Kindai University Faculty of Medicine; Osaka Japan

8. National Hospital Organization Kyushu Cancer Center; Fukuoka Japan

9. KKR Sapporo Medical Center; Sapporo Japan

10. Institute of Biomedical Research and Innovation Hospital; Hyogo Japan

11. Niigata Cancer Center Hospital; Niigata Japan

12. Gunma Prefectural Cancer Center; Gunma Japan

13. Shizuoka Cancer Center; Shizuoka Japan

14. Miyagi Cancer Center; Miyagi Japan

15. Osaka City General Hospital; Osaka Japan

16. National Hospital Organization Nagoya Medical Center; Aichi Japan

17. National Cancer Center Hospital East; Chiba Japan

18. National Hospital Organization Kinki-Chuo Chest Medical Center; Osaka Japan

19. Osaka Prefectural Medical Center for Respiratory and Allergic Diseases; Osaka Japan

20. Ono Pharmaceutical Co., Ltd; Osaka Japan

21. St. Luke's International Hospital; Tokyo Japan

Funder

Ono Pharmaceutical Co.,Ltd.

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/cas.13225/fullpdf

Reference21 articles.

1. Long-term realism and cost-effectiveness: primary prevention in combatting cancer and associated inequalities worldwide;Bray;J Natl Cancer Inst,2015

2. Non-small cell lung cancer, version 2.2013;Ettinger;J Natl Compr Canc Netw,2013

3. Lung cancer;Herbst;N Engl J Med,2008

4. Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer;Zielinski;Ann Oncol,2013

5. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Reck;Ann Oncol,2014

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Incidence of Cutaneous Immune-Related Adverse Events and Outcomes in Immune Checkpoint Inhibitor-Containing Regimens: A Systematic Review and Meta-Analysis;Cancers;2024-01-13

2. Targeting programmed cell death protein 1 (PD-1) for treatment of non-small-cell lung carcinoma (NSCLC); the recent advances;Pathology - Research and Practice;2023-06

3. Squamous cell carcinoma of the lung: improving the detection and management of immune-related adverse events;Expert Review of Anticancer Therapy;2022-01-26

4. Immune checkpoint inhibitor rechallenge in advanced or metastatic non-small cell lung cancer: a retrospective cohort study;Journal of Cancer Research and Clinical Oncology;2022-01-04

5. Adverse events of immunotherapy in non-small cell lung cancer: A systematic review and network meta-analysis;International Immunopharmacology;2022-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3